Table 3. Open in new tab Association of...

Model	FPG at Follow-Up (N = 5401)	2hPG at Follow-Up (N = 5401)	Glucose AUC at Follow-Up (N = 5370)	Type 2 Diabetes (N = 8746)	Cardiovascular Disease (N = 8198)
1	0.031	0.034	0.013	0.356	−1.018	0.115	−0.120	9.3E-19	−0.458	0.061	−0.101	1.0E-13	0.83	0.77 - 0.90	1.4E-06	0.75	0.67 - 0.83	4.6E-08
2	−0.063	0.035	−0.025	0.074	−1.142	0.117	−0.135	2.5E-22	−0.592	0.062	−0.131	2.6E-21	0.81	0.75 - 0.87	1.4E-07	0.81	0.72 - 0.91	2.2E-04
3	0.014	0.035	0.006	0.693	−0.845	0.116	−0.100	3.0E-13	−0.415	0.061	−0.092	1.1E-11	0.85	0.79 - 0.92	7.5E-05	0.82	0.73 - 0.92	8.2E-04
4	0.013	0.033	0.005	0.690	−0.852	0.108	−0.100	4.6E-15	−0.415	0.056	−0.092	9.9E-14	0.88	0.81 - 0.95	0.001	0.82	0.73 - 0.92	6.2E-04
5	−0.062	0.031	−0.025	0.047	−0.604	0.102	−0.071	3.7E-09	−0.247	0.053	−0.055	3.3E-06	0.88	0.81 – 0.95	0.001	0.82	0.73 – 0.92	5.0E-04

Model

FPG at Follow-Up (N = 5401)

2hPG at Follow-Up (N = 5401)

Glucose AUC at Follow-Up (N = 5370)

Type 2 Diabetes (N = 8746)

Cardiovascular Disease (N = 8198)

95% CI

0.031

0.034

0.013

0.356

−1.018

0.115

−0.120

9.3E-19

−0.458

0.061

−0.101

1.0E-13

0.83

0.77 - 0.90

1.4E-06

0.75

0.67 - 0.83

4.6E-08

−0.063

0.035

−0.025

0.074

−1.142

0.117

−0.135

2.5E-22

−0.592

0.062

−0.131

2.6E-21

0.81

0.75 - 0.87

1.4E-07

0.81

0.72 - 0.91

2.2E-04

0.014

0.035

0.006

0.693

−0.845

0.116

−0.100

3.0E-13

−0.415

0.061

−0.092

1.1E-11

0.85

0.79 - 0.92

7.5E-05

0.82

0.73 - 0.92

8.2E-04

0.013

0.033

0.005

0.690

−0.852

0.108

−0.100

4.6E-15

−0.415

0.056

−0.092

9.9E-14

0.88

0.81 - 0.95

0.001

0.82

0.73 - 0.92

6.2E-04

−0.062

0.031

−0.025

0.047

−0.604

0.102

−0.071

3.7E-09

−0.247

0.053

−0.055

3.3E-06

0.88

0.81 – 0.95

0.001

0.82

0.73 – 0.92

5.0E-04

Model	FPG at Follow-Up (N = 5401)	2hPG at Follow-Up (N = 5401)	Glucose AUC at Follow-Up (N = 5370)	Type 2 Diabetes (N = 8746)	Cardiovascular Disease (N = 8198)
1	0.031	0.034	0.013	0.356	−1.018	0.115	−0.120	9.3E-19	−0.458	0.061	−0.101	1.0E-13	0.83	0.77 - 0.90	1.4E-06	0.75	0.67 - 0.83	4.6E-08
2	−0.063	0.035	−0.025	0.074	−1.142	0.117	−0.135	2.5E-22	−0.592	0.062	−0.131	2.6E-21	0.81	0.75 - 0.87	1.4E-07	0.81	0.72 - 0.91	2.2E-04
3	0.014	0.035	0.006	0.693	−0.845	0.116	−0.100	3.0E-13	−0.415	0.061	−0.092	1.1E-11	0.85	0.79 - 0.92	7.5E-05	0.82	0.73 - 0.92	8.2E-04
4	0.013	0.033	0.005	0.690	−0.852	0.108	−0.100	4.6E-15	−0.415	0.056	−0.092	9.9E-14	0.88	0.81 - 0.95	0.001	0.82	0.73 - 0.92	6.2E-04
5	−0.062	0.031	−0.025	0.047	−0.604	0.102	−0.071	3.7E-09	−0.247	0.053	−0.055	3.3E-06	0.88	0.81 – 0.95	0.001	0.82	0.73 – 0.92	5.0E-04

Table 3.

Open in new tab

Association of Height at Baseline With Glycemic Parameters, Type 2 Diabetes, and CVD Events at Follow-Up in METSIM Participants Without Diabetes

Model	FPG at Follow-Up (N = 5401)				2hPG at Follow-Up (N = 5401)				Glucose AUC at Follow-Up (N = 5370)				Type 2 Diabetes (N = 8746)			Cardiovascular Disease (N = 8198)
Model	B	SE	β	P	B	SE	β	P	B	SE	β	P	HR	95% CI	P	HR	95% CI	P
1	0.031	0.034	0.013	0.356	−1.018	0.115	−0.120	9.3E-19	−0.458	0.061	−0.101	1.0E-13	0.83	0.77 - 0.90	1.4E-06	0.75	0.67 - 0.83	4.6E-08
2	−0.063	0.035	−0.025	0.074	−1.142	0.117	−0.135	2.5E-22	−0.592	0.062	−0.131	2.6E-21	0.81	0.75 - 0.87	1.4E-07	0.81	0.72 - 0.91	2.2E-04
3	0.014	0.035	0.006	0.693	−0.845	0.116	−0.100	3.0E-13	−0.415	0.061	−0.092	1.1E-11	0.85	0.79 - 0.92	7.5E-05	0.82	0.73 - 0.92	8.2E-04
4	0.013	0.033	0.005	0.690	−0.852	0.108	−0.100	4.6E-15	−0.415	0.056	−0.092	9.9E-14	0.88	0.81 - 0.95	0.001	0.82	0.73 - 0.92	6.2E-04
5	−0.062	0.031	−0.025	0.047	−0.604	0.102	−0.071	3.7E-09	−0.247	0.053	−0.055	3.3E-06	0.88	0.81 – 0.95	0.001	0.82	0.73 – 0.92	5.0E-04

Model	FPG at Follow-Up (N = 5401)				2hPG at Follow-Up (N = 5401)				Glucose AUC at Follow-Up (N = 5370)				Type 2 Diabetes (N = 8746)			Cardiovascular Disease (N = 8198)
Model	B	SE	β	P	B	SE	β	P	B	SE	β	P	HR	95% CI	P	HR	95% CI	P
1	0.031	0.034	0.013	0.356	−1.018	0.115	−0.120	9.3E-19	−0.458	0.061	−0.101	1.0E-13	0.83	0.77 - 0.90	1.4E-06	0.75	0.67 - 0.83	4.6E-08
2	−0.063	0.035	−0.025	0.074	−1.142	0.117	−0.135	2.5E-22	−0.592	0.062	−0.131	2.6E-21	0.81	0.75 - 0.87	1.4E-07	0.81	0.72 - 0.91	2.2E-04
3	0.014	0.035	0.006	0.693	−0.845	0.116	−0.100	3.0E-13	−0.415	0.061	−0.092	1.1E-11	0.85	0.79 - 0.92	7.5E-05	0.82	0.73 - 0.92	8.2E-04
4	0.013	0.033	0.005	0.690	−0.852	0.108	−0.100	4.6E-15	−0.415	0.056	−0.092	9.9E-14	0.88	0.81 - 0.95	0.001	0.82	0.73 - 0.92	6.2E-04
5	−0.062	0.031	−0.025	0.047	−0.604	0.102	−0.071	3.7E-09	−0.247	0.053	−0.055	3.3E-06	0.88	0.81 – 0.95	0.001	0.82	0.73 – 0.92	5.0E-04

Unstandardized B, SE, standardized β and P values were obtained from linear regression to evaluate the association of height with glycemic parameters at follow-up. Cox regression analyses was applied to evaluate the association of height with incident type 2 diabetes (N = 693) and the risk of CVD (N = 351). Model 1: unadjusted; Model 2: adjusted for age, waist, physical activity, smoking, alcohol, family history of diabetes, follow-up time (linear regression model), LDL cholesterol, and drug treatment of hypertension; Model 3: adjusted for variables in Model 2 and Matsuda ISI; Model 4: adjusted for variables in Model 2 and the disposition index; Model 5: adjusted for variables in Model 2 and corresponding trait at baseline for continuous traits; type 2 diabetes: adjusted for variables in Model 2 and 2hPG at baseline; CVD: adjusted for variables in Model 2 and presence or absence of type 2 diabetes.

Abbreviations: 2hPG, 2-hour plasma glucose; FPG, fasting plasma glucose.

This Feature Is Available To Subscribers Only